Advisor

Alister Thomson

Bristol Myers Squibb (Former)

Biography

Former Director of Transformation and Continuous Improvement at Bristol Myers Squibb

Alister is an experienced drug developer with direct involvement in 20 plus new drug approvals including immunotherapy drugs Opdivo and Yervoy. Alister advises Filtricine on clinical trial strategy.

Our Team

Dr. John Chant
CEO
Dr. Grace Xiaolu Yang
COO, VP of Research & Co-founder
Mike Partsuf
Senior Food Scientist
Emily Sinovic
Public Relations Consultant
Todd Lorenz
Clinical Development Consultant

Our Advisors

Dr. Mike P Snyder
Stanford University School of Medicine
Peter B Hutt
Senior Counsel at Covington & Burling LLP
Brad Barnes
Culinary Institute of America
Dr. Dariush Mozaffarian
Tufts University
Dr. Yung-Chi Cheng
Yale University School of Medicine
Dr. Danhua Xiao
Atlantic Health Metabolic Center
Dr. Joseph V Rodricks
Ramboll (formerly ENVIRON)
Alister Thomson
Bristol Myers Squibb (Former)
Jeff Depew
Sand Hill Angels
Dr. Wei Jiang
Medical Affairs at MorphoSys

Our Board of Directors

Dr. John Chant
CEO
Dr. Xiyan Li
Co-founder
Dr. Rami El Assal
Founding Partner at Boutique Venture Partners
Drew Lanza
Founding Partner at Berkeley Catalyst Fund
We are a clinical-stage biotechnology company based in the San Francisco Bay Area dedicated to developing novel food products for disease control.
© 2024 Filtricine, Inc. All Rights Reserved | by Wuilt
Privacy PolicyTerms of use